News | November 07, 2025
Philips reiterates FY25 outlook following steady Q3 performance
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
The company plans to use the funds to enhance its technology and forge new strategic partnerships with surgical robotics companies
Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval
During the quarter, Zydus Wellness completed the acquisition of Comfort Click Limited and its subsidiaries
Exemestane is a key therapeutic used in the treatment of certain types of breast cancer in postmenopausal women
The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Speakers are: Dr. Alok Khullar, Senior Technology Leader, Pidilite Industries; Dr. Kamlesh Pai Fondekar, Head - R&D, Godrej Agrovet; Dr. Hiten Mehta, Head - R&D (Chlor-Alkali), Aditya Birla Chemicals; Dr. Anil Kumar Soni, Head - Application Development, R&D, Clariant Chemicals India; Dr. Rupak Paul, Deputy General Manager – Formulation, Rallis India; Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals; and Pravin Prashant, Executive Editor, Indian Pharma Post
Glenmark will begin distribution in November 2025
This integrated center combines development, testing, evaluation, and industry-academia-research collaboration
Subscribe To Our Newsletter & Stay Updated
